Paroxysmal Tachycardia in Infancy <i>A Clinical and Experimental Study</i>

Lundberg, Åke

doi:10.1111/j.1651-2227.1963.tb03766.x

Cited by 16 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Altliough prognosis is usually good, mortality rates of 2-10% have been reported in some series (Giardina et al, 1972;Lundberg, 1963 is usually obtained only after 10-12 h. Such a delay may be hazardous if heart failure is present. If it is necessary to stop the arrhythmia quickly, it is possible to use vempamil or cadioversion.…”

Section: Discussionmentioning

confidence: 99%

The use of calcium gluconate priorto verapamil in infants with paroxysmal supraventricular tachycardia

Roguin

Shapir

Blazer

et al. 1984

Clinical Cardiology

View full text Add to dashboard Cite

Summary:Verapamil is a useful drug for treating supraventricular tachycardia; however, severe side effects occasionally have been reported in infants. We describe here our experience with the use of a 10 percent solution of intravenous calcium gluconate prior to the use of verapamil in infants with paroxysmal supraventricular tachycardia. In all the attacks verapamil converted the supraventricular tachycardia to sinus rhythm. We feel that calcium gluconate injected previous to verapamil can avoid the negative inotropic effects without interfering with the antiarrhythmic properties of veraparnil.

show abstract

Section: Discussionmentioning

confidence: 99%

The use of calcium gluconate priorto verapamil in infants with paroxysmal supraventricular tachycardia

Roguin

Shapir

Blazer

et al. 1984

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…The changes in the amplitude of the Pwaves which could be detected after interruption of the tachy cardia were directly correlated to the duration of tachycardia. Tachycardia of three-days duration generally resulted in measur able changes in amplitude in the young pigs [3J as in infants [4].…”

Section: Discussionmentioning

confidence: 99%

“…Changes in amplitude generally appear after tachycardia for three days with a rate of about 300 per minute [3|. Infants with paroxysmal tachycardia at a similar frequency develop similar changes in the atrial ECG [4].…”

mentioning

confidence: 99%

P-Wave Changes After Induced Supraventricular Tachycardia of Constant Duration in the Pig

Lundberg¹,

Schantz²

1967

Cardiology

View full text Add to dashboard Cite

“…The only natural history study of SVT was a retrospective report from 1963 in which 35% of 47 infants had a documented recurrence within 1 year, but only 7% had a recurrence between 1 year and a median follow-up of almost 4 years. 3 There are several descriptive studies in the literature reporting recurrence rates over lengthy observation periods. 2,4,12,22,28 However, these studies include older patients at presentation with mixed substrates (eg, Wolff-ParkinsonWhite syndrome, congenital heart disease).…”

mentioning

confidence: 99%

“…[8][9][10] As many as 50% of infants presenting with SVT have severe cardiomyopathy and heart failure because of unrecognized tachycardia. [2][3][4]11 Heart failure may progress to cardiovascular collapse and is the genesis of the associated 1% to 4% mortality. 2,5,[12][13][14] Due to concerns for morbidity and mortality and the challenges in detecting SVT in infants, 4,15 the general consensus among pediatric cardiologists who manage these patients has been to use medication to prevent recurrent SVT.…”

mentioning

confidence: 99%

The Study of Antiarrhythmic Medications in Infancy (SAMIS)

Sanatani

Potts

Reed

et al. 2012

Circ: Arrhythmia and Electrophysiology

View full text Add to dashboard Cite

Lake City, UT (S.P.E.); on behalf of the SAMIS investigators The online-only Data Supplement is available at http://circep.ahajournals.org/lookup/suppl/doi:10.1161/CIRCEP.112.972620/-/DC1. Correspondence to Shubhayan Sanatani, MD, Children's Heart Centre, British Columbia Children's Hospital, 1F9, 4480 Oak St, Vancouver, Canada V6H 3V4. E-mail ssanatani@cw.bc.ca Background-Supraventricular tachycardia (SVT) is one of the most common conditions requiring emergent cardiac care in children, yet its management has never been subjected to a randomized controlled clinical trial. The purpose of this study was to compare the efficacy and safety of the 2 most commonly used medications for antiarrhythmic prophylaxis of SVT in infants: digoxin and propranolol. Methods and Results-This was a randomized, double-blind, multicenter study of infants <4 months with SVT (atrioventricular reciprocating tachycardia or atrioventricular nodal reentrant tachycardia), excluding Wolff-Parkinson-White, comparing digoxin with propranolol. The primary end point was recurrence of SVT requiring medical intervention. Time to recurrence and adverse events were secondary outcomes. Sixty-one patients completed the study, 27 randomized to digoxin and 34 to propranolol. SVT recurred in 19% of patients on digoxin and 31% of patients on propranolol (P=0.25).No first recurrence occurred after 110 days of treatment. The 6-month recurrence-free status was 79% for patients on digoxin and 67% for patients on propranolol (P=0.34), and there were no first recurrences in either group between 6 and 12 months. There were no deaths and no serious adverse events related to study medication. Conclusions-There was no difference in SVT recurrence in infants treated with digoxin versus propranolol. The current standard practice may be treating infants longer than required and indicates the need for a placebo-controlled trial. Clinical Trial Registration Information-http://clinicaltrials.gov; NCT- Sanatani et al Treating Supraventricular Tachycardia in Infants 985during infancy. [8][9][10] As many as 50% of infants presenting with SVT have severe cardiomyopathy and heart failure because of unrecognized tachycardia. [2][3][4]11 Heart failure may progress to cardiovascular collapse and is the genesis of the associated 1% to 4% mortality. 2,5,[12][13][14] Due to concerns for morbidity and mortality and the challenges in detecting SVT in infants, 4,15 the general consensus among pediatric cardiologists who manage these patients has been to use medication to prevent recurrent SVT. In the context of this study, the term prophylaxis refers to the prevention of recurrent episodes of SVT. In a recent survey of pediatric cardiologists and electrophysiologists, Wong et al 16 reported that 98% of respondents recommend prophylactic medication when presented with a hypothetical case of an infant with SVT. Editorial see p 882 Clinical Perspective on p 991There are no randomized controlled trials addressing the most effective medicine for preventing recurrent SVT. The 2 most commo...

show abstract

Paroxysmal Tachycardia in Infancy A Clinical and Experimental Study

Cited by 16 publications

References 0 publications

The use of calcium gluconate priorto verapamil in infants with paroxysmal supraventricular tachycardia

The use of calcium gluconate priorto verapamil in infants with paroxysmal supraventricular tachycardia

P-Wave Changes After Induced Supraventricular Tachycardia of Constant Duration in the Pig

The Study of Antiarrhythmic Medications in Infancy (SAMIS)

Contact Info

Product

Resources

About